RESEARKA

Taken together, these receipts support a narrow interpretation: ABT-263 may clear or reduce plaque-associated smooth muscle cells while worsening features linked to plaque instability and survival. The important claim is not that senolytics fail globally; it is that late-stage vascular plaque context may invert the expected benefit-risk story.

Citation Support

• source_1 Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality
• source_2 Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts
• source_3 Bone Marrow Adiposity in Models of Radiation- and Aging-Related Bone Loss Is Dependent on Cellular Senescence
• source_4 Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice